Daniel Spasic

Avance Clinical is a full-service Contract Research Organization (CRO) headquartered in Australia, with extensive operations across New Zealand, Asia, North America, and Europe. As the market leaders in early phase clinical trials, we leverage the unique advantages of the Australian market, including rapid ethics approval, no IND requirement, and the 43.5% R&D tax rebate, to provide biotechs with an accelerated pathway to clinical success. Specializing in world-class operations, we guide biotechs from early pre-clinical development through to late-phase studies. With a focus on agility, innovation, and cost-effectiveness, we deliver fast results backed by robust, globally accepted data. With expertise spanning over 250+ indications, across all therapeutic areas, over the last three decades, Avance Clinical consistently delivers data recognized by key global regulators, including the TGA, FDA, EMA, MHRA, MFDS, and PDMA. What sets us apart is our personalized service tailored to each client, ensuring customized, flexible solutions rather than a one-size-fits-all approach. www.avancecro.com

Launched in the US in 2023, NuvoAir is a purpose-built, integrated specialty care platform that is reinventing the operating model through which care to complex cardiopulmonary patients is delivered. We emphasize the management of exacerbations, the key contributors to high healthcare costs and longitudinal care. Our platform empowers physicians, helping them maintain autonomy, deliver outstanding care and enhance their revenue in ways previously unattainable. By collaborating with health plans, risk-bearing entities, and innovative cardiologists and pulmonologists, we have redefined how patients with complex heart and lung issues, receive high quality care. To discover more about how NuvoAir is advancing high-value care in the cardiopulmonary space and to explore NuvoAirs extensive body of clinical evidence, visit nuvoair.com. Our recruiting email is talent@nuvoair.com, do not hesitate to reach out for any open position. Erin Murphree will be reaching out to you within short notice!

Trialbee is revolutionizing the patient recruitment ecosystem with technology, people, and passion. The company’s vendor-agnostic Honey Platform™ is a SaaS Patient Recruitment Platform that centralizes and standardizes all recruitment activities from every source, channel, and partner from interest through enrollment – providing unprecedented transparency and actionable insights for real-time patient tracking, higher-quality referrals that reduce site burden, and robust ROI reporting. Honey is surrounded by a team of Precision Recruitment experts who meet patients where they are in their journey with data-driven modeling based on consumer behavior and other real-world data, hyper-targeted digital outreach, two-step pre-qualification, and meaningful Omnichannel partners focused on patient advocacy, community engagement, and diversity. To take control of patient recruitment for your next study, visit http://www.trialbee.com/.

PathoQuest helps biopharmaceutical developers and manufacturers get their therapies to market with our leading expertise in GMP NGS-based biosafety testing and characterization services. As innovator companies continue to bring exciting novel therapies to market, there is a critical need for alternative biosafety and characterization strategies. This is especially the case for life-changing cell and gene therapies, as well as novel viral vaccines. Classical testing approaches, such as cell based assays, are often challenging to implement due to high volume requirements, as well as compatibility issues. Biosafety testing and characterization are key regulatory requirements for the release of biologic therapies. Therefore, alternative methods which can address these issues are of intense interest. There is also a drive from across industry and regulators to reduce, and eventually eliminate the use of animal models used in biosafety testing. The genomic approach of Next Generation Sequencing (NGS) can solve many of the challenges that are faced by developers and manufacturers, such as lower volume requirements and incompatibility with cell-based assays From our origins within the Institut Pasteur, PathoQuest is leading the way in expertise for the provision of GMP NGS based biosafety testing. Our expertise is underlined with over 20 peer reviewed publications on NGS applications in biosafety testing; as well as active participation in industry groups such as PDA, ADVTIG, CAACB and EFPIA. PathoQuest are committed to bringing this game-changing genomic approach to biopharmaceutical developers and manufacturers. PathoQuest has a global footprint, with operations in Europe (Paris) and North America (Wayne, PA); and have provided NGS biosafety testing services to over 100 of the top biopharmaceutical companies globally. Why not get in touch to see how we can help you with your biosafety testing strategy?

Avance Clinical is a full-service Contract Research Organization (CRO) headquartered in Australia, with extensive operations across New Zealand, Asia, North America, and Europe. As the market leaders in early phase clinical trials, we leverage the unique advantages of the Australian market, including rapid ethics approval, no IND requirement, and the 43.5% R&D tax rebate, to provide biotechs with an accelerated pathway to clinical success. Specializing in world-class operations, we guide biotechs from early pre-clinical development through to late-phase studies. With a focus on agility, innovation, and cost-effectiveness, we deliver fast results backed by robust, globally accepted data. With expertise spanning over 250+ indications, across all therapeutic areas, over the last three decades, Avance Clinical consistently delivers data recognized by key global regulators, including the TGA, FDA, EMA, MHRA, MFDS, and PDMA. What sets us apart is our personalized service tailored to each client, ensuring customized, flexible solutions rather than a one-size-fits-all approach. www.avancecro.com

Scantox is a Scandinavian preclinical GLP-accredited Contract Research Organization focused on pharmacology and regulatory toxicology. Based on decades of experience, we are a trusted partner for product development services within the pharmaceutical and medical device industries. The Scantox Group is headquartered in Denmark, with Swedish subsidiaries in Lund, Gothenburg and Solna. Our services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. The Scantox team is passionate about our common vision to improve the health of people, and all our processes are rooted in dedication and guided by a strong sense of purpose. Founded in 1977, Scantox is today owned by the Nordic based investment company Impilo. Certified as a 2023 Great Place To Work™. #pharmacology #toxicology #histopathology #pathology #minipigtoxicology

Proteros is a privately held early-stage services provider in structure-based drug discovery with a cutting-edge discovery engine tailored to unlock even the most technically challenging targets. Proteros’ work is built on scientific excellence and supports its clients to reach the right results and accelerate their overall research timelines. Proteros supports most of the world’s 20 largest pharma companies and more than 250 pharmaceutical and biotech partners in the US, Europe and Japan. For more information please visit www.proteros.com. As we continue to grow, we constantly look for committed, professional and energetic people with a high sense of responsibility, who enjoy challenges. We provide the environment for your career development and the tools you need to reach ambitious goals whilst striving for the highest standards of professional excellence. Join the Proteros team! http://www.proteros.de/company/career/ Proteros assumes no responsibilities of whatsoever nature for the suitability of the information contained herein for the customer. All references to offers for services, including research services, crystallography services, protein supply, cryo-EM and screening services are subject to a formal offer and contract to be agreed upon by Proteros and the customer. The conditions of such contract will be set forth in the respective order process.

Launched in the US in 2023, NuvoAir is a purpose-built, integrated specialty care platform that is reinventing the operating model through which care to complex cardiopulmonary patients is delivered. We emphasize the management of exacerbations, the key contributors to high healthcare costs and longitudinal care. Our platform empowers physicians, helping them maintain autonomy, deliver outstanding care and enhance their revenue in ways previously unattainable. By collaborating with health plans, risk-bearing entities, and innovative cardiologists and pulmonologists, we have redefined how patients with complex heart and lung issues, receive high quality care. To discover more about how NuvoAir is advancing high-value care in the cardiopulmonary space and to explore NuvoAirs extensive body of clinical evidence, visit nuvoair.com. Our recruiting email is talent@nuvoair.com, do not hesitate to reach out for any open position. Erin Murphree will be reaching out to you within short notice!